Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 plus pembrolizumab versus pembrolizumab in untreated advanced melanoma
NL-OMON53663Phase 3Not yet recruiting
- Sponsor
- IO Biotech
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of io102, IO103 + Montanide and pembrolizumab in melanoma and cutaneous malignancy (2 arms), sponsored by IO Biotech. Primary endpoint: Progression-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON53663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53663.